curculigoside profile

ID Source	ID
PubMed CID	158845
CHEMBL ID	258048
MeSH ID	M0453645

Synonym
curculigoside
curculigoside a
CHEMBL258048
[5-hydroxy-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]methyl 2,6-dimethoxybenzoate
85643-19-2
beta-d-glucopyranoside, 2-(((2,6-dimethoxybenzoyl)oxy)methyl)-4-hydroxyphenyl
unii-a6s7x76um5
a6s7x76um5 ,
AKOS015897151
S5457
DTXSID30234896
AC-33958
Q-100862
[5-hydroxy-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]methyl2,6-dimethoxybenzoate
Q5194662
HY-N0705
mfcd00800689
-2h-pyran-2-yloxy)benzyl 2,6-dimethoxybenzoate
trihydroxy-6-(hydroxymethyl)tetrahydro
curculigoside,(s)
5-hydroxy-2-((2s,3r,4s,5s,6r)-3,4,5-
HMS3886E06
CCG-269418
CS-0009721
AS-56484
(5-hydroxy-2-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}phenyl)methyl 2,6-dimethoxybenzoate
2-(((2,6-dimethoxybenzoyl)oxy)methyl)-4-hydroxyphenyl .beta.-d-glucopyranoside
beta-d-glucopyranoside, 2-[[(2,6-dimethoxybenzoyl)oxy]methyl]-4-hydroxyphenyl
C3504

Research Excerpts

Overview

Curculigoside is a phenolic glucoside present in the plant Curculigo orchioides Gaertn. It is a potentially effective drug for the treatment of IBI.

Excerpt	Reference	Relevance
"Curculigoside (Cur) is a natural component from Curculigo orchioides Gaertn, with various bioactivities. "	( Curculigoside Represses the Proliferation and Metastasis of Osteosarcoma via the JAK/STAT and NF-κB Signaling Pathways. Guo, H; Guo, Y; Han, L; Lai, F; Yu, J; Zheng, L, 2022)	3.61
"Curculigoside is a potentially effective drug for the treatment of IBI."	( Efficacy of curculigoside in protecting against ischemic brain injury through regulation of oxidative stress and NF-κB and PI3K/Akt expression. Liu, A; Wang, X; Wen, H; Wen, K; Xu, H; Xu, Y, 2023)	2.73
"Curculigoside is a natural phenolic glycoside compound produced by Curculigo orchioides Gaertn. "	( Curculigoside promotes osteogenic differentiation of ADSCs to prevent ovariectomized-induced osteoporosis. Xu, ZL; You, WL, 2021)	3.51
"Curculigoside is a phenolic glucoside present in the plant Curculigo orchioides Gaertn."	( Curculigoside augments cell-mediated immune responses in metastatic tumor-bearing animals. Kuttan, G; Murali, VP, 2016)	2.6
"Curculigoside (CCGS) is a major bioactive compound isolated from the rhizome of Curculigo orchioides Gaertn."	( Neuroprotective effects of curculigoside against NMDA-induced neuronal excitoxicity in vitro. Li, XB; Liu, HB; Liu, SB; Tian, Z; Yu, W; Zhang, N; Zhao, MG, 2012)	1.4

Effects

Curculigoside has an extensive pharmacological activity, including estrogen-like, improving sexual behavior, antiosteoporotic, antioxidant, immunomodulatory and neuroprotective effects. It has shown protective effects against rat cortical neuron damage in vivo.

Excerpt	Reference	Relevance
"Curculigoside has an extensive pharmacological activity, including estrogen-like, improving sexual behavior, antiosteoporotic, antioxidant, immunomodulatory and neuroprotective effects. "	( Pharmacokinetic and tissue distribution profile of curculigoside after oral and intravenously injection administration in rats by liquid chromatography-mass spectrometry. Han, T; He, YJ; Lv, L; Qin, LP; Xu, HT; Yuan, TT; Zhang, ND; Zhang, QY; Zhao, L, 2015)	2.11
"Curculigoside has been shown to decrease oxidative stress and inflammatory reactions in many disorders, but its effects during hepatic ischemia-reperfusion injury (IRI) remain unknown. "	( Curculigoside mitigates hepatic ischemia/reperfusion-induced oxidative stress, inflammation, and apoptosis via activation of the Nrf-2/HO-1 pathway. Du, P; Fu, C; Li, Y; Luo, K; Xiao, J; Xiao, Q; Zhang, X, )	3.02
"Curculigoside has an extensive pharmacological activity, including estrogen-like, improving sexual behavior, antiosteoporotic, antioxidant, immunomodulatory and neuroprotective effects. "	( Pharmacokinetic and tissue distribution profile of curculigoside after oral and intravenously injection administration in rats by liquid chromatography-mass spectrometry. Han, T; He, YJ; Lv, L; Qin, LP; Xu, HT; Yuan, TT; Zhang, ND; Zhang, QY; Zhao, L, 2015)	2.11
"Curculigoside A has shown protective effects against rat cortical neuron damage in vivo. "	( Mechanisms of angiogenesis in a Curculigoside A-treated rat model of cerebral ischemia and reperfusion injury. He, J; Hou, J; Jiang, W; Lin, F; Ye, L; Zhong, Y; Zhu, H, 2015)	2.14

Treatment

Excerpt	Reference	Relevance
"Curculigoside pre‑treatment significantly improved cell viability, decreased cell apoptosis and LDH activity, and reduced the infarct size and myocardial apoptosis in vitro and ex vivo, respectively."	( Curculigoside attenuates myocardial ischemia‑reperfusion injury by inhibiting the opening of the mitochondrial permeability transition pore. Chen, Y; Guo, Y; Jia, D; Liu, S; Wu, N; Zhao, Y, 2020)	2.72

Pharmacokinetics

The validated LC-MS/MS method was successfully applied to the pharmacokinetic and tissue distribution study of curculigoside in rats.

Excerpt	Reference	Relevance
" The validated method was successfully applied to the pharmacokinetic and tissue distribution study of curculigoside in rats."	( Pharmacokinetic and tissue distribution profile of curculigoside after oral and intravenously injection administration in rats by liquid chromatography-mass spectrometry. Han, T; He, YJ; Lv, L; Qin, LP; Xu, HT; Yuan, TT; Zhang, ND; Zhang, QY; Zhao, L, 2015)	0.88
" A rapid and sensitive method with UPLC-MS was developed and fully validated for the first time in the pharmacokinetic analysis for quantification of CC in rat plasma."	( Pharmacokinetic and Metabolism Studies of Curculigoside C by UPLC-MS/MS and UPLC-QTOF-MS. Li, P; Lin, H; Liu, J; Tan, J; Wang, C; Wang, H; Wu, D; Yin, J; Zhu, H, 2018)	0.75

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Assay ID	Title	Year	Journal	Article
AID320801	Inhibition of beta amyloid 25-35 fibril formation at 10 uM	2008	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2	New polyphenols active on beta-amyloid aggregation.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (8.33)	29.6817
2010's	23 (63.89)	24.3611
2020's	10 (27.78)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	37 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
4-hydroxybenzoic acid 4-hydroxybenzoic acid : A monohydroxybenzoic acid that is benzoic acid carrying a hydroxy substituent at C-4 of the benzene ring.	2.04	1	monohydroxybenzoic acid	algal metabolite; plant metabolite
orcinol orcinol: used as reagent for pentoses, lignin, beet sugar, saccharoses, arabinose & diastase; RN given refers to parent cpd; structure. orcinol : A 5-alkylresorcinol in which the alkyl group is specified as methyl.	2.6	1	5-alkylresorcinol; dihydroxytoluene	Aspergillus metabolite
malondialdehyde Malondialdehyde: The dialdehyde of malonic acid.. malonaldehyde : A dialdehyde that is propane substituted by two oxo groups at the terminal carbon atoms respectively. A biomarker of oxidative damage to lipids caused by smoking, it exists in vivo mainly in the enol form.	2.17	1	dialdehyde	biomarker
acetylcysteine N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.	2.31	1	acetylcysteine; L-cysteine derivative; N-acetyl-L-amino acid	antidote to paracetamol poisoning; antiinfective agent; antioxidant; antiviral drug; ferroptosis inhibitor; geroprotector; human metabolite; mucolytic; radical scavenger; vulnerary
n-methylaspartate N-Methylaspartate: An amino acid that, as the D-isomer, is the defining agonist for the NMDA receptor subtype of glutamate receptors (RECEPTORS, NMDA).. N-methyl-D-aspartic acid : An aspartic acid derivative having an N-methyl substituent and D-configuration.	2.07	1	amino dicarboxylic acid; D-alpha-amino acid; D-aspartic acid derivative; secondary amino compound	neurotransmitter agent
glucose, (beta-d)-isomer beta-D-glucose : D-Glucopyranose with beta configuration at the anomeric centre.. (1->4)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->4) linkages.. (1->3)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->3) linkages.	4.93	32	D-glucopyranose	epitope; mouse metabolite
epigallocatechin gallate epigallocatechin gallate: a steroid 5alpha-reductase inhibitor and antimutagen in green tea (Camellia sinensis). (-)-epigallocatechin 3-gallate : A gallate ester obtained by the formal condensation of gallic acid with the (3R)-hydroxy group of (-)-epigallocatechin.	2.04	1	flavans; gallate ester; polyphenol	antineoplastic agent; antioxidant; apoptosis inducer; geroprotector; Hsp90 inhibitor; neuroprotective agent; plant metabolite
gallocatechol (-)-epigallocatechin : A flavan-3,3',4',5,5',7-hexol having (2R,3R)-configuration.	2.04	1	catechin; flavan-3,3',4',5,5',7-hexol	antioxidant; food component; plant metabolite
epicatechin gallate epicatechin gallate: a steroid 5alpha-reductase inhibitor; RN given refers to the (cis)-isomer; structure given in first source; isolated from green tea. (-)-epicatechin-3-O-gallate : A gallate ester obtained by formal condensation of the carboxy group of gallic acid with the (3R)-hydroxy group of epicatechin. A natural product found in Parapiptadenia rigida.	2.04	1	catechin; gallate ester; polyphenol	EC 3.2.1.1 (alpha-amylase) inhibitor; EC 3.2.1.20 (alpha-glucosidase) inhibitor; metabolite
delphinidin delphinidin: RN given refers to parent cpd;. delphinidin : An anthocyanidin cation consisting of benzopyrylium with hydroxy substituents at the 3-, 5- and 7-positions and a 3,4,5-trihydroxyphenyl group at the 2-position. It is a plant pigment responsible for the colours of the plants of the genera Viola and Delphinium.	2.04	1	5-hydroxyanthocyanidin	antineoplastic agent; biological pigment; plant metabolite
cyanidin cyanidin: RN given refers to parent cpd; structure. cyanidin cation : An anthocyanidin cation that is flavylium substituted at positions 3, 3', 4', 5 and 7 by hydroxy groups.	2.04	1	5-hydroxyanthocyanidin	antioxidant; metabolite; neuroprotective agent
malvidin malvidin: RN given refers to parent cpd; coloring agent from flowers of Malvaviscus conzatti. malvidin : An anthocyanidin cation that is delphinidin carrying methyl substituents at positions 3' and 5'.	2.04	1	5-hydroxyanthocyanidin	biological pigment; metabolite
cyanidin 3-o-beta-d-glucopyranoside cyanidin 3-O-beta-D-glucoside : An anthocyanin cation that is a cyanidin cation linked to a beta-D-glucosyl moiety at position 3.	2.04	1	anthocyanin cation; beta-D-glucoside; monosaccharide derivative	metabolite
malvidin-3-glucoside malvidin 3-O-beta-D-glucoside : An anthocyanin cation consisting of malvidin having a beta-D-glucosyl residue attached at the 3-hydroxy position.	2.04	1	anthocyanin cation; aromatic ether; beta-D-glucoside	metabolite
e-z cinnamic acid cinnamic acid : A monocarboxylic acid that consists of acrylic acid bearing a phenyl substituent at the 3-position. It is found in Cinnamomum cassia.. trans-cinnamic acid : The E (trans) isomer of cinnamic acid	2.13	1	cinnamic acid	plant metabolite
resveratrol trans-resveratrol : A resveratrol in which the double bond has E configuration.	2.04	1	resveratrol	antioxidant; phytoalexin; plant metabolite; quorum sensing inhibitor; radical scavenger
h 89 N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide: structure given in first source. N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide : A member of the class of isoquinolines that is the sulfonamide obtained by formal condensation of the sulfo group of isoquinoline-5-sulfonic acid with the primary amino group of N(1)-[3-(4-bromophenyl)prop-2-en-1-yl]ethane-1,2-diamine. It is a protein kinase A inhibitor.. (E)-N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide : A N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide in which the double bond adopts a trans-configuration.	2.6	1	N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide
trans-4-coumaric acid hydroxycinnamic acid : Any member of the class of cinnamic acids carrying one or more hydroxy substituents.. trans-4-coumaric acid : The trans-isomer of 4-coumaric acid.. 4-coumaric acid : A coumaric acid in which the hydroxy substituent is located at C-4 of the phenyl ring.	2.04	1	4-coumaric acid	food component; mouse metabolite; plant metabolite
caffeic acid trans-caffeic acid : The trans-isomer of caffeic acid.	2.04	1	caffeic acid	geroprotector; mouse metabolite
osteoprotegerin Osteoprotegerin: A secreted member of the TNF receptor superfamily that negatively regulates osteoclastogenesis. It is a soluble decoy receptor of RANK LIGAND that inhibits both CELL DIFFERENTIATION and function of OSTEOCLASTS by inhibiting the interaction between RANK LIGAND and RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B.	2.78	3	long-chain fatty acid
dinoprostone prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.	2.13	1	prostaglandins E	human metabolite; mouse metabolite; oxytocic
pterostilbene [no description available]	2.04	1	diether; methoxybenzenes; stilbenol	anti-inflammatory agent; antineoplastic agent; antioxidant; apoptosis inducer; hypoglycemic agent; neuroprotective agent; neurotransmitter; plant metabolite; radical scavenger
acid phosphatase Acid Phosphatase: An enzyme that catalyzes the conversion of an orthophosphoric monoester and water to an alcohol and orthophosphate. EC 3.1.3.2.	2.11	1
cytochrome c-t Cytochromes c: Cytochromes of the c type that are found in eukaryotic MITOCHONDRIA. They serve as redox intermediates that accept electrons from MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX III and transfer them to MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX IV.	2.25	1
cyclin d1 Cyclin D1: Protein encoded by the bcl-1 gene which plays a critical role in regulating the cell cycle. Overexpression of cyclin D1 is the result of bcl-1 rearrangement, a t(11;14) translocation, and is implicated in various neoplasms.	2.1	1

Condition	Relationship Strength	Studies
Bone Cancer [description not available]	2.41	1
Osteogenic Sarcoma [description not available]	2.41	1
Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES.	2.41	1
Osteosarcoma A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)	7.41	1
Acute Post-Traumatic Stress Disorder [description not available]	2.6	1
Stress Disorders, Post-Traumatic A class of traumatic stress disorders with symptoms that last more than one month.	2.6	1
Cerebral Infarction, Middle Cerebral Artery [description not available]	2.6	1
Acute Brain Injuries [description not available]	2.6	1
Brain Injuries Acute and chronic (see also BRAIN INJURIES, CHRONIC) injuries to the brain, including the cerebral hemispheres, CEREBELLUM, and BRAIN STEM. Clinical manifestations depend on the nature of injury. Diffuse trauma to the brain is frequently associated with DIFFUSE AXONAL INJURY or COMA, POST-TRAUMATIC. Localized injuries may be associated with NEUROBEHAVIORAL MANIFESTATIONS; HEMIPARESIS, or other focal neurologic deficits.	2.6	1
Infarction, Middle Cerebral Artery NECROSIS occurring in the MIDDLE CEREBRAL ARTERY distribution system which brings blood to the entire lateral aspects of each CEREBRAL HEMISPHERE. Clinical signs include impaired cognition; APHASIA; AGRAPHIA; weak and numbness in the face and arms, contralaterally or bilaterally depending on the infarction.	2.6	1
Colitis Gravis [description not available]	2.76	2
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.96	3
Colitis Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.	7.6	1
Colitis, Ulcerative Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.	2.76	2
Rheumatoid Arthritis [description not available]	7.98	3
Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.	2.98	3
Bone Loss, Osteoclastic [description not available]	2.88	3
Iron Overload An excessive accumulation of iron in the body due to a greater than normal absorption of iron from the gastrointestinal tract or from parenteral injection. This may arise from idiopathic hemochromatosis, excessive iron intake, chronic alcoholism, certain types of refractory anemia, or transfusional hemosiderosis. (From Churchill's Illustrated Medical Dictionary, 1989)	2.21	1
Anoxemia [description not available]	2.55	2
Injury, Myocardial Reperfusion [description not available]	2.25	1
Hypoxia Sub-optimal OXYGEN levels in the ambient air of living organisms.	2.55	2
Age-Related Osteoporosis [description not available]	2.55	2
Osteoporosis Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.	7.55	2
Bone Loss, Perimenopausal [description not available]	2.31	1
Osteoporosis, Postmenopausal Metabolic disorder associated with fractures of the femoral neck, vertebrae, and distal forearm. It occurs commonly in women within 15-20 years after menopause, and is caused by factors associated with menopause including estrogen deficiency.	2.31	1
Ischemia A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.	2.17	1
Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.	2.17	1
Depression Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.	7.21	1
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	2.1	1
Angiogenesis, Pathologic [description not available]	2.1	1
Age-Related Memory Disorders [description not available]	2.11	1
Memory Disorders Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions.	2.11	1
Cerebral Ischemia [description not available]	2.49	2
Injury, Ischemia-Reperfusion [description not available]	2.11	1
Brain Ischemia Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.	2.49	2
Reperfusion Injury Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.	7.11	1
Adjuvant Arthritis [description not available]	2.13	1
Metastase [description not available]	2.13	1
Experimental Neoplasms [description not available]	2.13	1
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	2.13	1
Skin Aging The process of aging due to changes in the structure and elasticity of the skin over time. It may be a part of physiological aging or it may be due to the effects of ultraviolet radiation, usually through exposure to sunlight.	2.05	1
Acute Confusional Senile Dementia [description not available]	2.07	1
Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.	2.07	1
Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)	2.07	1

curculigoside

Cross-References

Synonyms (29)

Research Excerpts

Overview

Effects

Treatment

Pharmacokinetics

Bioassays (1)

Research

Studies (36)

Market Indicators

Research Demand Index: 23.40

Study Types

curculigoside

Cross-References

Synonyms (29)

Research Excerpts

Overview

Effects

Treatment

Pharmacokinetics

Bioassays (1)

Research

Studies (36)

Market Indicators

Research Demand Index: 23.40

Study Types

Related Drugs (25)

Related Conditions (44)